QC
SLN

Quadrature Capital’s Silence Therapeutics SLN Stock Holding History

Quadrature Capital’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54,380
Closed -$331K – 1805
2025
Q4 		$331K Buy
+54,380
New +$348K ﹤0.01% 810

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Quadrature Capital's SLN Position: Q1 2026 in Review

Quadrature Capital sold out of Silence Therapeutics (SLN) in Q1 2026, closing a stake of 54,380 shares — an estimated $331K sold.

Quadrature Capital first reported a position in SLN in Q4 2025 and held it in 1 quarter. The position peaked at $331K in Q4 2025. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Quadrature Capital reported no remaining Silence Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 54,380 Silence Therapeutics shares in Q1 2026, an estimated $331K.
  • Quadrature Capital first reported a position in Silence Therapeutics in Q4 2025 and held it in 1 quarter.
  • Quadrature Capital's Silence Therapeutics position peaked at $331K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.